Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 41, Issue 6, Pages 612-619Publisher
WILEY
DOI: 10.1177/00912700122010492
Keywords
-
Categories
Ask authors/readers for more resources
Montelukast, a leukotriene receptor antagonist, has demonstrated efficacy and tolerability in the treatment of asthma in patients age 6 years and older. The purpose of this open, one-period, multicenter population pharmacokinetic study was to identify a chewable tablet (CT) dose of montelukast for administration to children ages 2 to 5 years with asthma, yielding a single-dose pharmacokinetic profile (area under the plasma concentration-time curve [AUC]) comparable to that of the 10 mg film-coated tablet (FCT) dose in adults. Because patient numbers were small and the volume of blood that could be collected from individual 2- to 5-year-old patients was limited, a population pharmacokinetic approach was used to estimate population AUC (AUC(pop)). The 4 mg CT dose of montelukast was well tolerated and yielded on AUC(pop) (2721 ng.h/ml) similar to that of the adult AUC(pop) (2595 ng.h/mL) observed after a 10 mg FCT dose. These results support the selection of a 4 mg once-daily CT dose of montelukast for future efficacy and safety studies in children ages 2 to 5 years with asthma. (C) 2001 the American College of Clinical Pharmacology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available